Personalis PSNL 深 滬
交易中 04-01 10:48:26 美东时间
6.64
+0.270
+4.24%
華盛通- 最 高6.75
- 今 開6.56
- 成交量 24.34万股
- 最 低 6.49
- 昨 收 6.37
- 總市值 6.95亿
- 52周最高 11.50
- 市盈率 靜 --
- 換手率 0.23%
- 52周最低 3.09
- 委 比 -92.68%
- 總股本 1.05亿
- 歷史最高 53.46
- 量 比 0.78
- 振 幅 4.08%
- 歷史最低 0.8906
- 每 手 1
- 風險率 2.04%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Cathie Wood's weekly recap: adds JOBY, CRSP, TEM, sells TER, TXG, CRCL
Cathie Wood’s Ark Invest reshuffled positions across its ETFs during last week, adding positions to gene-editing and AI healthcare names while trimming genomics tools and semiconductor equipment holdi...
03-16 19:05
Personalis Announces The Publication Of PREDICT-DNA Study In The Journal Of Clinical Oncology, Showing That Ultrasensitive Molecular Residual Disease Testing With Next Personal Can Perform Better Than Current Standard Approaches In Predicting Patient Outcomes Following Neoadjuvant Therapy
The prospective study followed 227 patients with Triple-Negative (TNBC) and HER2+ breast cancer across more than 24 leading US cancer centers. The results demonstrate the ability of NeXT Personal to provide a more
03-12 18:57
Personalis PREDICT-DNA study links post-neoadjuvant ctDNA to 4x-9x higher breast cancer relapse risk
Personalis PREDICT-DNA study links post-neoadjuvant ctDNA to 4x-9x higher breast cancer relapse risk Personalis reported results from the prospective PREDICT-DNA study in the Journal of Clinical Oncology evaluating the NeXT Personal ctDNA assay for monitoring molecular residual disease in triple-neg
03-12 18:01
美股大行评级 | 最高582美元！博通获多家机构上调目标价；GENI、Okta、Rigetti Computing、Veeva Systems、Wix.com遭多家机构下调目标价
今日重点评级关注：韦德布什：维持TScan Therapeutics"跑赢大市"评级，目标价从4美元升至5美元；HC Wainwright & Co.：维持莱斯康制药"买入"评级，目标价从4美元升至6美元
03-06 11:58
美股大行评级 | 下调居多！多邻国、Elastic、Flutter、欧特克、Zscaler等遭多家机构下调目标价
今日重点评级关注：巴克莱：维持C4 Therapeutics"超配"评级，目标价从5美元升至7美元；富国银行：维持Agilon Health"超配"评级，目标价从1美元升至1.5美元
03-02 14:08
Breaking Down Personalis: 5 Analysts Share Their Views
Across the recent three months, 5 analysts have shared their insights on Person...
02-27 21:00
Needham Maintains Buy on Personalis, Raises Price Target to $12
Needham analyst Mike Matson maintains Personalis (NASDAQ:PSNL) with a Buy and raises the price target from $10 to $12.
02-27 19:52
Personalis shares are trading lower after the company reported mixed Q4 financial results and issued FY26 sales guidance with its midpoint below estimates.
Personalis shares are trading lower after the company reported mixed Q4 financi...
02-27 06:02
Earnings Scheduled For February 26, 2026
Companies Reporting Before The Bell • Enovis (NYSE:ENOV) is estimated to report...
02-26 19:11
Personalis Inc. to Attend TD Cowen 46th Annual Healthcare Conference
Personalis Inc. to Attend TD Cowen 46th Annual Healthcare Conference Personalis, Inc. will participate in the TD Cowen 46th Annual Healthcare Conference on Tuesday, March 3, 2026, at the Boston Marriott Copley Place in Boston, MA. For more information, visit www.personalis.com and connect with Perso
02-18 05:01
